PubMed:24715845 JSONTXT

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":142,"end":155},"obj":"HP_0003002"},{"id":"T2","span":{"begin":142,"end":155},"obj":"HP_0100013"},{"id":"T3","span":{"begin":149,"end":155},"obj":"HP_0002664"},{"id":"T4","span":{"begin":336,"end":341},"obj":"HP_0011088"}],"text":"Side effects of standard adjuvant and neoadjuvant chemotherapy regimens according to age groups in primary breast cancer.\nBACKGROUND: Elderly breast cancer patients are underrepresented in clinical trials and this leads to a lack of knowledge regarding the tolerance and side effects of modern chemotherapy regimens, especially in dose-dense (dd) or dose-intensified combination.\nPATIENTS AND METHODS: In this analysis, data from 4 German, randomized (neo-)adjuvant trials, including anthracycline-based chemotherapy, were evaluated for toxicity, compliance and feasibility. Patients were grouped according to age.\nRESULTS: Of the 4,775 patients, 73.6% were \u003c 60 years, 15.8% were 60-64 years and 10.6% were \u003e 64 years. The patients' compliance decreased with increasing age, the rate of therapy discontinuations was 10.3%; 16.0% were \u003e 64 years old (p \u003c 0.001). The rate of dose reductions also increased with increasing age in the docetaxel/doxorubicin/cyclophosphamide (TAC) (p overall = 0.02) and 5-fluorouracil/epirubicin-cyclophosphamide (FE120C) (p overall \u003c 0.001) treatment groups. Neutropenia grade 3 + 4 in patients of \u003e 64 years was 77% in FE120C- compared to 55% in TAC-treated patients (with primary granulocyte colony-stimulating factors (G-CSFs)). The incidence of febrile neutropenia (FN) was lowest in the regimens without additional taxanes. FN in patients aged \u003e 64 years was lower in the FE120C- than in TAC-and dd-doxorubicin/docetaxel-treated groups.\nCONCLUSION: The range and intensity of toxicity increased with age. Neutropenia did not increase significantly in the dd groups; the highest rate was seen in FE120C-treated patients. FE120C without G-CSFs is not an option in patients older than 64 years."}

{"project":"Allie","denotations":[{"id":"SS1_24715845_2_0","span":{"begin":331,"end":341},"obj":"expanded"},{"id":"SS2_24715845_2_0","span":{"begin":343,"end":345},"obj":"abbr"},{"id":"SS1_24715845_10_0","span":{"begin":1214,"end":1252},"obj":"expanded"},{"id":"SS2_24715845_10_0","span":{"begin":1254,"end":1260},"obj":"abbr"},{"id":"SS1_24715845_11_0","span":{"begin":1281,"end":1300},"obj":"expanded"},{"id":"SS2_24715845_11_0","span":{"begin":1302,"end":1304},"obj":"abbr"}],"relations":[{"id":"AE1_24715845_2_0","pred":"abbreviatedTo","subj":"SS1_24715845_2_0","obj":"SS2_24715845_2_0"},{"id":"AE1_24715845_10_0","pred":"abbreviatedTo","subj":"SS1_24715845_10_0","obj":"SS2_24715845_10_0"},{"id":"AE1_24715845_11_0","pred":"abbreviatedTo","subj":"SS1_24715845_11_0","obj":"SS2_24715845_11_0"}],"text":"Side effects of standard adjuvant and neoadjuvant chemotherapy regimens according to age groups in primary breast cancer.\nBACKGROUND: Elderly breast cancer patients are underrepresented in clinical trials and this leads to a lack of knowledge regarding the tolerance and side effects of modern chemotherapy regimens, especially in dose-dense (dd) or dose-intensified combination.\nPATIENTS AND METHODS: In this analysis, data from 4 German, randomized (neo-)adjuvant trials, including anthracycline-based chemotherapy, were evaluated for toxicity, compliance and feasibility. Patients were grouped according to age.\nRESULTS: Of the 4,775 patients, 73.6% were \u003c 60 years, 15.8% were 60-64 years and 10.6% were \u003e 64 years. The patients' compliance decreased with increasing age, the rate of therapy discontinuations was 10.3%; 16.0% were \u003e 64 years old (p \u003c 0.001). The rate of dose reductions also increased with increasing age in the docetaxel/doxorubicin/cyclophosphamide (TAC) (p overall = 0.02) and 5-fluorouracil/epirubicin-cyclophosphamide (FE120C) (p overall \u003c 0.001) treatment groups. Neutropenia grade 3 + 4 in patients of \u003e 64 years was 77% in FE120C- compared to 55% in TAC-treated patients (with primary granulocyte colony-stimulating factors (G-CSFs)). The incidence of febrile neutropenia (FN) was lowest in the regimens without additional taxanes. FN in patients aged \u003e 64 years was lower in the FE120C- than in TAC-and dd-doxorubicin/docetaxel-treated groups.\nCONCLUSION: The range and intensity of toxicity increased with age. Neutropenia did not increase significantly in the dd groups; the highest rate was seen in FE120C-treated patients. FE120C without G-CSFs is not an option in patients older than 64 years."}